📊 GBCS Key Takeaways
Is Selectis Health, Inc.. (GBCS) a Good Investment?
Selectis Health exhibits severe financial distress with negative stockholders' equity of -$5.7M, indicating the company is technically insolvent. The company is unprofitable with negative operating and net margins, minimal liquidity (0.19x current ratio), and insufficient cash reserves ($417K) relative to debt obligations ($18.5M long-term debt). While operating cash flow is positive at $1.2M, this cannot offset the fundamental deterioration in financial position and lack of clear path to profitability.
Selectis Health shows some operating stabilization, with revenue growth, positive operating cash flow, and near-breakeven net income. However, those improvements are outweighed by very weak financial health: negative equity, severe liquidity stress, and inadequate interest coverage indicate a fragile capital structure. The core question is not growth alone, but whether the business can sustain operations and service debt without balance-sheet repair.
Why Buy Selectis Health, Inc.. Stock? GBCS Key Strengths
- Positive operating cash flow of $1.2M demonstrates some cash generation capability
- Revenue growth of 7.4% YoY shows modest top-line expansion
- Positive free cash flow of $851K provides limited financial flexibility
- Revenue grew 7.4% year over year, indicating the top line is still expanding
- Operating cash flow and free cash flow are positive, which supports short-term operating viability
- Net loss is relatively small versus revenue, suggesting the company is close to break-even at the bottom line
GBCS Stock Risks: Selectis Health, Inc.. Investment Risks
- Negative stockholders' equity of -$5.7M indicates technical insolvency and bankruptcy risk
- Critically low liquidity with current ratio of 0.19x creates immediate solvency concerns
- Persistent operating losses (-$1.2M) and negative net margins (-0.7%) with no clear profitability trajectory
- High leverage with $18.5M long-term debt versus only $417K cash, creating debt service vulnerability
- Negative interest coverage ratio (-0.5x) indicates inability to service debt from operations
- Negative stockholders equity signals accumulated balance-sheet impairment and limits financial flexibility
- Current and quick ratios of 0.19x indicate acute liquidity pressure and potential refinancing dependence
- Negative interest coverage shows operations are not currently earning enough to comfortably support debt costs
Key Metrics to Watch
- Stockholders' equity trend - critical to monitor if returning to positive territory
- Operating margin improvement - must achieve profitability to reverse distress trajectory
- Liquidity position and cash burn rate - essential given minimal cash reserves
- Debt refinancing or restructuring activities - bankruptcy risk mitigation efforts
- Current ratio and cash balance relative to near-term obligations
- Interest coverage and total debt trend versus operating cash flow
Selectis Health, Inc.. (GBCS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 2.7% FCF margin may limit capital allocation flexibility. The current ratio below 1.0x warrants monitoring of short-term liquidity.
GBCS Profit Margin, ROE & Profitability Analysis
GBCS vs Real Estate Sector: How Selectis Health, Inc.. Compares
How Selectis Health, Inc.. compares to Real Estate sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Selectis Health, Inc.. Stock Overvalued? GBCS Valuation Analysis 2026
Based on fundamental analysis, Selectis Health, Inc.. has mixed fundamental signals relative to the Real Estate sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Selectis Health, Inc.. Balance Sheet: GBCS Debt, Cash & Liquidity
GBCS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Selectis Health, Inc..'s revenue has grown significantly by 41% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.80 indicates the company is currently unprofitable.
GBCS Revenue Growth, EPS Growth & YoY Performance
GBCS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.0M | -$211.6K | $-0.08 |
| Q2 2025 | $9.6M | -$240.4K | $-0.08 |
| Q1 2025 | $9.5M | -$656.0K | $-0.22 |
| Q3 2024 | $9.0M | -$337.9K | $-0.11 |
| Q2 2024 | $8.9M | -$240.4K | $-0.08 |
| Q1 2024 | $9.5M | -$1.0M | $-0.34 |
| Q3 2023 | $9.0M | $37.1K | $-0.07 |
| Q2 2023 | $8.9M | $228.7K | $0.34 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Selectis Health, Inc.. Dividends, Buybacks & Capital Allocation
GBCS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Selectis Health, Inc.. (CIK: 0000727346)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GBCS
What is the AI rating for GBCS?
Selectis Health, Inc.. (GBCS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 89% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GBCS's key strengths?
Claude: Positive operating cash flow of $1.2M demonstrates some cash generation capability. Revenue growth of 7.4% YoY shows modest top-line expansion. ChatGPT: Revenue grew 7.4% year over year, indicating the top line is still expanding. Operating cash flow and free cash flow are positive, which supports short-term operating viability.
What are the risks of investing in GBCS?
Claude: Negative stockholders' equity of -$5.7M indicates technical insolvency and bankruptcy risk. Critically low liquidity with current ratio of 0.19x creates immediate solvency concerns. ChatGPT: Negative stockholders equity signals accumulated balance-sheet impairment and limits financial flexibility. Current and quick ratios of 0.19x indicate acute liquidity pressure and potential refinancing dependence.
What is GBCS's revenue and growth?
Selectis Health, Inc.. reported revenue of $31.8M.
Does GBCS pay dividends?
Selectis Health, Inc.. pays dividends, with $0.4M distributed to shareholders in the trailing twelve months.
Where can I find GBCS SEC filings?
Official SEC filings for Selectis Health, Inc.. (CIK: 0000727346) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GBCS's EPS?
Selectis Health, Inc.. has a diluted EPS of $-0.08.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GBCS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Selectis Health, Inc.. has a SELL rating with 89% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GBCS stock overvalued or undervalued?
Valuation metrics for GBCS: ROE of N/A (sector avg: 8%), net margin of -0.7% (sector avg: 20%). Compare these metrics with sector averages to assess valuation.
Should I buy GBCS stock in 2026?
Our dual AI analysis gives Selectis Health, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GBCS's free cash flow?
Selectis Health, Inc..'s operating cash flow is $1.2M, with capital expenditures of $387.0K. FCF margin is 2.7%.
How does GBCS compare to other Real Estate stocks?
Vs Real Estate sector averages: Net margin -0.7% (avg: 20%), ROE N/A (avg: 8%), current ratio 0.19 (avg: 1.5).